Physician profile
Jennifer E Lawrence
NPI 1396827457
$6,280.82
in general payments reported to CMS, 2019-2025
52 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,230 · 2020: $410 · 2021: $469 · 2022: $950 · 2023: $1,096 · 2024: $1,060 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,942 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,941.50 |
| Education | $280.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $511.32 | 2019-2024 | Jardiance, Mounjaro, Lyumjev |
| Novo Nordisk INC | $477.61 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $434.11 | 2019-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Dexcom, INC. | $408.81 | 2019-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $386.28 | 2020-2025 | Korlym |
| Amgen INC. | $369.57 | 2019-2025 | Evenity, Tepezza, Repatha |
| Astrazeneca Pharmaceuticals LP | $362.91 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $304.69 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.22 | 2019-2025 | Jardiance |
| Medtronic, INC. | $231.28 | 2021-2024 | Minimed 780g |
| Insulet Corporation | $207.63 | 2021-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $195.80 | 2019-2024 | |
| Tandem Diabetes Care, INC. | $182.44 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $140.88 | 2019-2020 | |
| Medtronic Minimed, INC. | $130.50 | 2019-2020 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $117.94 | 2020-2022 | |
| Horizon Therapeutics Plc | $100.62 | 2022-2023 | Tepezza |
| Amneal Pharmaceuticals LLC | $94.16 | 2024-2025 | Unithroid |
| Ibsa Pharma INC. | $86.93 | 2023-2025 | Licart, Tirosint, Tirosint |
| Amarin Pharma, INC. | $83.61 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $79.27 | 2019 | |
| Aurinia Pharma U.S., INC. | $76.32 | 2024-2025 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $70.85 | 2019 | |
| Antares Pharma, INC. | $65.44 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Ucb, INC. | $60.06 | 2024-2025 | Bimzelx, Cimzia |
| Xeris Pharmaceuticals, INC. | $60.06 | 2020-2023 | Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $59.28 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $55.36 | 2024 | Isturisa, Signifor Lar |
| Radius Health, INC. | $45.57 | 2023-2024 | Tymlos |
| Amryt Pharma Holdings LTD | $40.02 | 2022 | |
| Endo Pharmaceuticals INC. | $39.80 | 2022 | |
| Pfizer INC. | $38.39 | 2024-2025 | |
| Mannkind Corporation | $37.89 | 2024 | |
| Ascensia Diabetes Care US INC. | $37.21 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $34.49 | 2019-2023 | Seglentis, Livalo |
| Conmed Corporation | $31.35 | 2025 | Conmed Biliary |
| Abbvie INC. | $28.61 | 2024 | |
| Companion Medical, INC. | $28.37 | 2020 | |
| Senseonics, Incorporated | $28.00 | 2019 | |
| Sequel Med Tech, LLC | $26.37 | 2025 | Twiist |
| Mallinckrodt Hospital Products INC. | $25.84 | 2025 | Acthar |
| Averitas Pharma INC. | $20.70 | 2025 | Qutenza |
| Tonix Medicines, INC. | $20.35 | 2025 | Tonmya |
| Almatica Pharma LLC | $19.69 | 2024 | Teriparatide |
| Lifescan, INC. | $18.93 | 2021 | |
| Halozyme INC | $18.77 | 2023 | |
| Chiesi USA, INC. | $18.24 | 2025 | Myalept |
| Ani Pharmaceuticals, INC. | $18.02 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $17.78 | 2024 | Actemra |
| Glaxosmithkline, LLC. | $17.55 | 2020 | |
| Nevro Corp. | $16.60 | 2021 | |
| Valeritas, INC. | $16.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.